WeChat Share

Details

2014 CABA Biomedical Investment & Entrepreneurship Symposium

2014 美中生物医药协会投资与创业研讨会

Presented by

Chinese-American BioMedical Association (CABA)

1:00 PM –7:00 PM, Saturday, October 25, 2014

Doubletree Suites Boston, 

400 Soldiers Field Road, Boston, MA 02134

Admission

CABA members: FREE; Non-members: $30. On-site membership registration available ($30 annual membership fee due). You can also register online at www.cabaweb.org.

Driving Direction & Parking

Please enter the hotel parking garage from Storrow Drive. Parking is free (ticket will be validated onsite).

Symposium Organizing Committee Chair

Eric SHI

Co-Chairs

Wendy YANG, Yin CHEN, Liping ZHOU

Members

Qingqing CAO, Qinglin CHE, Zhihong CHEN, Chaoyang DAI, Ellen FAN, Jo LEE, Hao LI, Shiwen LIN, Susan QU, Jian SHAO, Ze TIAN, Yihan WANG, Zhigang WANG, Zhiyong YANG, Xiangyang YU, Phil ZHANG

 

For information about CABA and upcoming events, please check CABA Web site: www.cabaweb.org.

Registration

Type Sales End Price Quantity

Registration for an active CABA member

2014-10-25 19:30 $0

Student annual membership

2014-10-25 19:30 $15

Annual membership + registration

2014-10-25 19:30 $30

Registration only

2014-10-25 19:30 $30

Registration for an active CABA members (Membership will be checked onsite)

2014-10-25 19:30 $0

About CABA

Chinese-American BioMedical Association (CABA) is a 501(C)(3) not-for-profit professional organization registered in Massachusetts since May 2007. CABA is committed to promote public awareness of advancement in the pharmaceutical and biomedical industry, professional interactions in the fields of life sciences, global biomedical innovations and business development. As the majority of its members are scientists with Chinese heritage, CABA will operate in two important areas. One is to serve as a platform for its members to develop and advance their careers in the US pharmaceutical and biomedical industry, the other is to serve as a bridge to connect members including corporate members with the scientific and business resources in China thus facilitating collaboration between the pharmaceutical and biomedical industries across continents. To fulfill these goals, we will organize scientific and business symposia, conferences, workshops, in US and China, as well as social events to promote networking and communication among members. We will bring together members, scientists, professionals, government officials and business leaders across the continents under a collaborative environment and achieve their best potentials. 

CABA is a volunteer-based society. We rely on members to contribute their time and efforts to build the organization. We rely on corporate members and sponsors to raise fund to support the above activities. We value integrity, honesty, professionalism, community service, scientific excellence, responsibility and accountability. We invite you to explore our organization, and we are confident you will share our values and are interested in becoming a member, devoting your time or efforts, or sponsoring CABA activities. In summary, CABA is built by its members and serves for its members.


www.cabaweb.org

Meeting Agenda

2014-10-25 12:30 ~19:30
registration
2014-10-25 13:30 ~19:30
Opening Remarks
Eric Shi, PhD, Symposium Chair
2014-10-25 13:35 ~19:30
Welcome address
Zhiyong Yang, PhD, CABA president
2014-10-25 13:40 ~19:30
Plenary Session I, Phil Zhang, PhD, JD, Chair
2014-10-25 13:40 ~19:30
Keynote: Investing in Early Stage Innovation and Biotech
Jonathan Fleming, General partner, Oxford Bioscience Partners
2014-10-25 14:15 ~19:30
Technology Transfer from Universities
Wanni Davis, PhD, Senior Associate, Beth Israel Deaconess Medical Center
2014-10-25 14:45 ~19:30
Increasing Role of Incubator / Innovation Park
Joon Woon Chong, VP, Sembcorp Development Ltd - Singapore/Chengdu
2014-10-25 15:15 ~19:30
Coffee Break
2014-10-25 15:35 ~19:30
Plenary Session II, Wendy Yang, MBA
2014-10-25 15:35 ~19:30
Keynote: Biopharma Investing from "Outsider's" Perspective
Adam Koppel, PhD, Chief Strategy Officer, Biogen Idec
2014-10-25 16:10 ~19:30
Investment in Life Science Companies in both China and US
Sofie Qiao, PhD, Managing Director, Wuxi Venture Fund
2014-10-25 16:40 ~19:30
Panel discussion: Opportunities and Challenges for Entrepreneurs (moderator: Yin Chen)
Yi Sun, PhD, Founder, Nanocs, Inc. ; Liying Yan, President, EpigenDx, Inc. ; Charles Ye, PhD, Founder, Acesys Pharmatech; Jean Qiu, PhD, Founder and CSO, Nexcelom Bioscience; Boke Zhang, Ph.D., Founder &CEO, Mayly Life Sciences
2014-10-25 17:30 ~19:30
Networking Reception

Speakers

Jonathan Fleming
General Partner, Oxford Bioscience Partners
Jonathan Fleming is the Managing Partner of Oxford Bioscience Partners, an international venture capital firm specializing in life science technology based investments, with offices in Boston, Massachusetts and Seoul, Korea. He is a General Partner of the Korea-Seoul Life Science Fund. Mr. Fleming has been in the investment business for over twenty seven years, starting and financing growth companies in the United States, Europe, Israel and Asia. Prior to joining OBP in 1996, he was a Founding General Partner of MVP Ventures in Boston, MA. He began his investment career with TVM Techno Venture Management in Munich, Germany. Mr. Fleming has also co-founded Medica Venture Partners, a venture capital investment firm specializing in early stage healthcare and biotechnology companies in Israel. Mr. Fleming is a director of several public companies including Xencor (NASDAQ: XNCR) and several private companies. He is also a director of Leerink Swann, a Boston based investment bank specializing in healthcare companies. In addition, Mr. Fleming is a Senior Lecturer at the MIT Sloan School of Business and a Member of the Board of NEHI, a healthcare oriented think tank and policy advocacy group. Mr. Fleming is on the Chancellor’s Commercialization Advisory Board of the University of Texas System. Mr. Fleming holds a Master's degree in Public Administration from Princeton University and a Bachelor of Arts degree from the University of California, Berkeley.
Wanni Davis
Senior Associate, Beth Israel Deaconess Medical Center
Wanni A. Davis, M.B.A., Ph.D., is a Senior Associate in the Technology Ventures Office (TVO), a technology transfer unit within basic research enterprise at Beth Israel Deaconess Medical Center (BIDMC). As a teaching hospital of Harvard Medical School, BIDMC conducts a wide range of biomedical research from basic science discoveries to novel translational innovations leading to development of new drugs, diagnostics and devices. The mission of TVO is to help translate BIDMC research and innovation for the society's benefit. Wanni manages all aspects of the technology transfer process from faculty outreach to identification and evaluation of new inventions, IP management, marketing, and commercializing early-stage life science technologies. She has negotiated numerous collaboration, sponsored research, option and license agreements and has also facilitated the formation of many start-up companies. She has business development/licensing experience in several academic settings, including Massachusetts General Hospital, Tufts University/Tufts Medical Center, and University of Massachusetts, and previously performed basic research at Harvard Medical School. She holds a Ph.D. with a focus on Cancer and Immunology from the University of Michigan and B.S./M.B.A. from Eastern Michigan University, and a B.B.A. from Assumption University.
Joon Woon Chong
Vice President, Sembcorp Development Ltd.
Joon Woon leads the team responsible for Sembcorp Development’s strategic planning and investment promotion, and business development for land development opportunities. Prior to joining Sembcorp in 2012, Joon Woon spent 14 years in the Singapore Economic Development Board (EDB) with 7 years based out of EDB’s United States offices. His last stint in the United States was at the San Francisco office as Regional Director of Western Americas, overseeing EDB’s multiple offices responsible for investment promotion from the western half of the United States (including Texas), western Canada and Central America. Joon Woon was the Director of Electronics before he left the EDB. He led the team responsible for the planning, industry development and investment promotion efforts in Singapore’s electronics sector, which was the largest contributor of manufacturing investments for Singapore and accounted for more than 5% of Singapore’s GDP. Joon Woon graduated from the National University of Singapore with a Bachelor’s degree (Honours) in Electronics Engineering with a specialisation in semiconductors.
Adam Koppel
Senior Vice Present & Chief Strategy Officer, Biogen Idec
Dr. Koppel has served in this position since May 2014. He joined Biogen Idec from Brookside Capital, the public equity affiliate of Bain Capital, where he joined in 2003, serving as managing director since 2009. Prior to Brookside Capital, he was an associate principal of the McKinsey Healthcare Practice. Dr. Koppel serves on the board of directors of PTC Therapeutics, a biopharmaceutical company. Dr. Koppel holds Bachelor and Master of Arts degrees in History and Science from Harvard College and earned an M.D. and Ph.D. in Molecular Neurobiology from the University of Pennsylvania. He also received an M.B.A. from the University of Pennsylvania’s Wharton School.
Sofie Qiao
Managing director, Wuxi Venture Fund at Wuxi
Dr. Qiao has over 15 years of experience as a successful executive and entrepreneur in the biotech industry. After receiving a BA in chemistry from Harvard and PhD in organic chemistry from MIT, she worked at Genzyme (now Sanofi), McKinsey & Company, Syrrx (now Takeda California), and Discovery Partners International (now Galapagos and Infinity Pharmaceuticals), across a variety of functions including research, strategy consulting and business development. In 2006, she cofounded a US/China hybrid small molecule discovery company LEAD Therapeutics, Inc, assembled a management team and raised Series A financing of $17 million. LEAD was acquired by BioMarin in 2010 for up to $97 million, mostly for its PARP inhibitor, then at preclinical stage, and now in Phase III clinical development at BioMarin. Since then, she engaged in various entrepreneurial and consulting activities, before joining WuXi in late2013.
Yin Chen
Consultant, Independent business development consultant
Dr. Yin Chen is a biotech entrepreneur. After working for an early stage biotech company as a founding scientist and Chief Scientist Officer for over 9 years, he co-foundered and became President/CEO of MTT Pharmaceuticals in 2008. Dr. Chen is currently an independent business development consultant for product marketing, product in/out-licensing, and venture fund raising. Dr. Chen received his Bachelor of Science degree from University of Science & Technology China, Master of Science degree from Shanghai Institute of Biochemistry and Ph.D degree from University of Maine. He subsequently completed his postdoc training at Harvard Medical School/Beth Israel Deaconess Medical Center. In 2013, Dr. Chen earned an EMBA from Jack Welch Management Institute.
Jean Qiu
Founder and CSO, Nexcelom Bioscience
Dr. Jean Qiu is the founder and President of Nexcelom Bioscience LLC. From the basement of her home, she started the company in 2003, with the goal of automating manual cell counting and cell-based assays on the biologist’s lab bench using image cytometry technologies. Today, the Cellometer-branded cell counting systems and Celigo-branded image cytometer for cells in micro-plates, consisting of instrument, software and consumables and reagent kits, are distributed globally and used in laboratories of pharmaceutical companies, government institutions and universities for biomedical research, such as cancer research, vaccine development and drug discovery. The company has now grown to nearly 50 people in Lawrence, Massachusetts, San Diego, California, Manchester, UK, and Shanghai, China, where the dedicated entrepreneurial team covers everything from engineering and manufacturing to marketing and customer service. Prior to Nexcelom Bioscience, Dr. Qiu worked for 3M Company for more than a decade, as a product commercialization team leader in Health Care Group, Research Specialist in the Material Application Laboratory, and Senior Research Engineer in the Corporate Research Laboratory, where she was a co-inventor of the first blue-green semiconductor laser. She also worked for a biotech start-up, as its Director of Process Development and Manufacturing, where she developed plastic optical sensors and established its manufacturing process. Dr. Qiu earned her PhD in Electrical Engineering from Purdue University in 1990 and her BS is Electrical Engineering from Nanjing Institute of Technology in China. She has published numerous papers in peer-reviewed academic journals and holds 23 US patents. Awards received include the Rank Prize for Opto-Electronics, London, UK, 1993, for the invention of the blue-green diode laser, and 3M Company’s Excellent Record of Invention Award. In 2006, Dr. Qiu was honored by the Boston Woman’s Business Journal with the Hall of Fame Award.
Yi Sun
Co-Founder & executive director, Nanocs Inc
Nanocs Inc. (www.nanocs.net) is a nanobiotech company dedicated to the development of innovative biomedical products for drug delivery, formulation and diagnostic applications. Dr. Sun obtained his Ph.D. degree in Chemistry from New York University and finished his post-doctor training in Harvard Medical School and Mass general hospital. Dr. Sun is the major inventor of tens of US patents. The technology developed by Dr. Sun has been licensed by several US companies and the products based on his invention have been sold over 50 countries. Dr. Sun currently also serves on advisor board to several US biotech and nanotech companies.
Liying Yan
President, Epigen Dx. Inc.
Charles Ye
Founder and CEO, Acesys Pharmatech
Charles (Yuanzan) Ye is the founder and CEO of Acesys Pharmatech since 2004. With more than 6 years of experience at Schering Plough Pharmaceutical in New Jersey as medicinal chemist and then financial analyst, Charles has extensive experience on drug discovery and financial management. Acesys Pharmatech is focused on Drug Discovery and API Manufacturing. Through investment and acquisition, Acesys Pharmatech acquired a China based GMP manufacturing company in Jiangsu and a USA cGMP manufacturing company in New Jersey (API Inc). He designed and built Small Molecule Discovery Platform at China Medical City in 2009-2010. He also organized several international meeting in Nanjing and is currently director of several committees in Nanjing. Now he is building a research incubator in Nanjing area to promote research collaboration and help start-up companies grow quickly.
Boke Zhang
Founder and CEO, Mayly Life Sciences
Dr. Boke Zhang is the Chairman and CEO of Mayly Life Science, a biotech company specialized in advanced nano-transdermal delivery technology development and applications in X-ceutical products (i.e.: pharmaceuticals, cosmeceuticals and nutraceuticals) with lines of more than 30 cosmeceutical products currently on market (www.meilyskin.com). He is the former Vice President of Product Development of Anterios Inc., managing both large (biologics) & small drug molecules with company's proprietary novel drug delivery system for product development from preclinical to clinical phases. In the past he also held various senior management positions such as Director of Analytical Development in Millennium Pharmaceuticals, and Deputy Director & Site Head of Analytical R&D of Baxter’s Cherry Hill site in NJ. Prior to that, he was the Senior Manager of Global Analytical Development of Pfizer for products from discovery, development to commercial scales. Overall, Dr. Zhang has more than 20 year pharmaceutical industry experience in developing drug candidates from discovery through development to commercial market.

Date Time

2014-10-25 12:30 - Start

2014-10-25 19:30 - End

Ended
Address
  • 400 Soldiers Field Road , BOSTON  MA  02134

Contact Us

Your Name: *
Your Email: *
Cell phone:
Subject: *
Message: *